The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction.
Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy against breast cancer. CD40 ligand (CD40L), a key molecule in the interface between T-lymphocytes and DCs, seems to be instrumental in achieving that goal. Commenting on our data that CD40L protects circulating DCs from apoptosis induced by breast tumor products, Lenahan and Avigan highlighted the potential of CD40L for immunotherapy. We expand on that argument by pointing to additional findings that CD40L not only rescues genuine DCs but also functionally improves populations of immature antigen-presenting cells that fill the DC compartment in patients with breast cancer.
Pinzon-Charry
Alberto
A
Schmidt
Chris W
CW
López
José Alejandro
JA
D000938:Antigen-Presenting Cells; D017209:Apoptosis; D001943:Breast Neoplasms / Q000628:therapy*; D023201:CD40 Ligand / Q000502:physiology*; D003713:Dendritic Cells / Q000502:physiology*; D005260:Female; D006801:Humans; D007167:Immunotherapy
D023201:CD40 Ligand